Priority Review Voucher Expansion Could Be Bad, Program Creator Says
This article was originally published in The Pink Sheet Daily
Congress should be cautious about adding categories because more vouchers will mean a lower price for companies who want to sell them, Duke economist Ridley and Novartis exec Régnier argue.
You may also be interested in...
Is the lower sale price making the opportunity for a priority review voucher less an incentive for orphan development?
BioMarin's sale of voucher earned with approval of rare pediatric disease drug Brineura the fourth publicly disclosed voucher sale this year with a price tag between $125m and $150m.
Just as the tulip craze eventually subsided, it appears the pharma industry's infatuation with priority review vouchers also may be waning, as Sarepta sells its voucher for only $125m.